Unquoted Biotechs Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Unquoted Biotechs

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: nigel bates who started this subject	1/15/2004 4:25:33 PM
From: John McCarthy	of 253

Synthon Reaches Pact With GlaxoSmithKline Thu Jan 15 12:59:41 2004 Synthon Reaches Pact With GlaxoSmithKline CHAPEL HILL, N.C. -(Dow Jones)- Synthon Pharmaceuticals Ltd. and GlaxoSmithKline PLC (NYSE:GSK - News) settled patent litigation related to Synthon's Pexeva which competes with GSK's antidepressant Paxil. GlaxoSmithKline previously filed suit in the U.S. District Court for the Middle District of North Carolina alleging that Synthon infringed three of GSK's patents, Synthon said in a press release Thursday. The settlement agreement tosses out all three patent infringement claims, which includes a royalty payable to GlaxoSmithKline. Synthon will be able to immediately market its Pexeva product and anticipates a product launch in the first half of 2004. A GlaxoSmithKline spokeswoman said Pexeva's drug is not a generic substitute for Paxil. She declined to disclose settlement terms. -Jenny Park; Dow Jones Newswires; 201-938-5400 Key(s): GlaxoSmithKline omniomix.com

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next